Assessing the perforation site of cardiac tamponade during radiofrequency catheter ablation using gas analysis of pericardial effusion

Yumi Katsume, MD,,* Akiko Ueda, MD,† Takato Mohri, MD,* Mika Tashiro, MD,* Yuichi Momose, MD,* Noriko Nonoguchi, MD,* Kyoko Hoshida, MD,* Yosuke Miwa, MD,* Ikuko Togashi, MD,† Toshiaki Sato, MD,† Kyoko Soejima, MD*

From the *Department of Cardiovascular Medicine, Kyorin University Hospital, Tokyo, Japan, and †Division of Advanced Arrhythmia Management, Kyorin University Hospital, Tokyo, Japan.

BACKGROUND The incidence of pericardial effusion (PE) during radiofrequency catheter ablation (CA) for atrial fibrillation is approximately 1%. PE is a major complication during CA, but there has been limited literature about the perforation site responsible.

OBJECTIVE This study aimed to retrospectively investigate the characteristics of the procedure and the patients in whom PE developed during CA.

METHODS Of 1363 consecutive patients who underwent catheter ablation from January 2015 to June 2019 in Kyorin University Hospital, we reviewed patients who developed PE during CA.

RESULTS PE during CA occurred in 18 (1.32%) patients (median age, 71 [interquartile range (IQR) 65–77] years, 7 women). The median body mass index was 24 (IQR 20–27). Target arrhythmias for CA of patients with PE include atrial fibrillation (AF) (n = 13, 72%), premature ventricular contraction (n = 2, 11%), ventricular tachycardia (n = 1, 6%), atrial flutter (n = 1, 6%), and orthodromic reciprocating tachycardia (n = 1, 6%). Seventeen patients required pericardiocentesis, resulting in 300 (IQR 192.5–475) mL of drainage. Two patients required emergency surgical repair, and 1 died from aortic dissection. Based on the gas analysis, the drained blood was of venous origin in 47% of the total events and 54% of AF ablation.

CONCLUSION PE caused by a diagnostic catheter in the right heart is not uncommon, even in AF ablation.

KEYWORDS Atrial fibrillation; Catheter ablation; Gas analysis; Pericardial effusion; Pericardiocentesis

Introduction

Pericardial effusion (PE) due to cardiac perforation is a known major complication of radiofrequency (RF) catheter ablation (CA). The reported incidence of PE during CA was 0.5%–4.0% for atrial fibrillation (AF)1,2 and 2% for ventricular tachycardia (VT).3,4 It can be caused by mechanical trauma during catheter manipulation, inadvertent injury during transseptal puncture, or steam pop during CA. The majority of PE cases are usually controlled by pericardiocentesis, but some require emergency surgical repair and blood transfusion. Only a limited number of studies identified the perforation site either by emergency surgery or by coronary angiography.5,6,7 There is a paucity of data on the perforation site in patients who developed PE during CA. In a report by Bunch and colleagues,5 2 of 15 patients who required open surgery had a perforation site at the left atrial dome, but the perforation site was not evaluated in the remaining patients. We sought to investigate the characteristics of procedures and patients with PE and retrospectively identify the possible perforation site using gas analysis of PE.

Methods

Study population

The clinical description of this research was approved by the Institutional Review Board of Kyorin University Hospital. Written informed consent was obtained from each patient. We reviewed 1363 consecutive patients who underwent CA from January 2015 to June 2019 in our hospital. Of these patients, 18 patients who developed PE were retrospectively analyzed.

Set-up and workflow

All procedures were performed under mild-to-moderate conscious sedation using dexmedetomidine, fentanyl, and thiopental. All patients had continuous arterial blood pressure monitored with an arterial line and received oxygen (5 L/min) either with a face mask or noninvasive positive-pressure ventilation in case of sleep apnea syndrome. Our usual
practice has been to skip anticoagulation on the morning of CA, except for patients on warfarin or patients on direct oral anticoagulant with a history of stroke or low left atrial appendage blood flow velocity. Unfractionated heparin was administered during the left heart CA to maintain the activated clotting time (ACT) of ≥300 seconds. Diagnostic catheters were introduced via femoral and internal jugular veins and positioned at the coronary sinus (CS), tricuspid annulus, His recording site, and right ventricle (RV) apex according to the physician’s decision. A 3-dimensional electroanatomic mapping system was created using CARTO (Biosense Webster, Diamond Bar, CA), Ensite (Abbott Laboratories, Chicago, IL), or Rhythmia (Boston Scientific, Cambridge, MA), except in patients who were ablated using the cryoballoon system. As per our safety protocol, we used intracardiac echocardiography (ICE) just for the transseptal puncture and usually remove it prior to the insertion of the ablation catheter to minimize venous access.

Management of PE

Patients were monitored with continuous arterial pressure monitoring. Our usual practice is to check the heart border motion in left anterior oblique (LAO) view if the blood pressure declines. If reduced cardiac motion was recognized, transthoracic echocardiography or ICE was used to check the PE. If cardiac tamponade was identified, transthoracic echocardiography or ICE was used to check the PE. If cardiac tamponade was identified, pericardiocentesis via the subxiphoid and drainage were performed with volume expansion and administration of norepinephrine. If unfractionated heparin was used during the procedure, protamine was administered intravenously to reverse anticoagulation. If the bleeding was not controlled, blood transfusion and emergency surgical repair were performed. Continuation of the procedure was decided by the physician according to the patient’s condition.

Gas analysis of PE and blood

We evaluated whether there was a difference of more than 36.9 mm Hg in \( pO_2 \) between PE and peripheral venous blood gas, which was sampled at the same time of PE drainage, except in the case where PE could be clearly assessed as of venous origin from the \( pO_2 \) value. If peripheral venous blood gas was not collected at the time, we set \( pO_2 > 55 \) mm Hg and \( sO_2 > 84\% \) as the cut-off for arterial origin.

Statistical analysis

For descriptive statistics, numbers were stated as the exact number or percentage. Continuous variables were reported as median and first and third interquartile range (IQR).

Results

Of 1363 patients who underwent CA, 18 (1.32%) patients developed PE during the procedures, and PE was seen in 1.30% of atrial tachycardia / AF ablation, 1.75% of atrial flutter ablation, 2.13% of atrioventricular reentrant tachycardia ablation, and 1.83% of VT / premature ventricular contraction (PVC) ablation. Of the patients who underwent atrial tachycardia / AF ablation, 91.5% were taking direct oral anticoagulants. Characteristics of the 18 patients with PE are shown in Table 1. All events were detected in the catheter laboratory and no subsequent or chronic PE was observed. The median age was 71 years (IQR 65–77), and 7 (39%) were women. The median body mass index was 24 (IQR 20–27), and 2 patients had sleep apnea syndrome. Sixteen (89%) patients were on anticoagulants and 1 (6%) patient was taking antiplatelets. Target arrhythmias for CA of patients with PE were AF in 13 (72%), PVC in 2 (11%), VT associated with nonischemic cardiomyopathy in 1 (6%), atrial flutter in 1 (6%), and orthodromic reciprocation tachycardia in 1 (6%) (Figure 1). One patient treated with a cryoballoon catheter developed PE. Characteristics of the procedures and outcomes are shown in Table 2. Diagnostic catheters were positioned at the His recording area in 1 case, at His-RV in 1 case, at CS in 17 cases, and at Halo in 1 patient. Multipolar mapping catheter was used in 17 (94%) procedures. For the ablation catheter, 10 (56%) with contact force and 8 (44%) without contact force were used. The median of the last ACT prior to the cardiac tamponade was 271 (IQR 245–296) seconds. Seventeen (94%) patients required pericardiocentesis, resulting in 300 (IQR 192.5–475) mL of drainage. Two (11%) patients required emergency surgical repairs, and 1 (6%) patient died from tamponade caused by the incidental aortic dissection despite attempts at emergency surgical repair. Reasons for PE identification were declined blood pressure in 15 (83%) and reduced cardiac motion in the LAO view in 3 (17%).

Timing of the PE detection

Figure 2 summarizes the timing of PE detection. PE was recognized during mapping in 2 (11%), during CA in 4 (22%), after cardioversion in 2 (11%), during induction by burst pacing and program stimulation in 2 (11%), post CA mapping in 3 (17%), and at the time of sheath extraction post procedure in 5 (28%) patients. Of these patients, 3 (patients 1, 2, and 8) had ICE catheter placement during the
Table 1  Characteristics of patients with pericardial effusion

| Pt | Age (years) | Sex | BMI  | Dx         | LVEF (%) | Anti coagulants | Deep sedation | SAS | Comorbidity | BNP (pg/mL) | Risk score* |
|----|-------------|-----|------|-----------|----------|-----------------|----------------|-----|-------------|-------------|-------------|
| 1  | 65          | M   | 27.3 | AF        | 62       | +               | +              | +   | HTN, DM     | 75.5        | 2           |
| 2  | 70          | F   | 19.3 | AF        | 61       | +               | -              | -   | -           | 30.7        | 2           |
| 3  | 64          | F   | 17.5 | AF        | 62       | -               | +              | -   | -           | 1086        | 3           |
| 4  | 68          | F   | 27.5 | AF        | 58       | +               | -              | -   | HTN         | 22.9        | 2           |
| 5  | 72          | M   | 26.3 | AF        | 65       | +               | -              | -   | HTN         | 30.3        | 1           |
| 6  | 79          | M   | 23.5 | AF        | 54       | +               | -              | -   | HTN         | 71.1        | 1           |
| 7  | 81          | F   | 25.3 | AF        | 58       | +               | +              | -   | HTN         | 47.1        | 3           |
| 8  | 73          | F   | 21.3 | AF        | 63       | +               | -              | +   | HTN         | 228         | 3           |
| 9  | 78          | F   | 22.6 | AF        | 63       | +               | -              | -   | HTN         | 43.1        | 2           |
| 10 | 72          | M   | 25.2 | VT        | NICM     | 57              | -              | +   | -           | 444         | 1           |
| 11 | 55          | M   | 17.8 | PVC       | Post PVI | 54              | -              | -   | HTN         | 15.8        | 0           |
| 12 | 76          | M   | 19.9 | AF        | 60       | +               | -              | -   | HTN         | 339         | 1           |
| 13 | 78          | F   | 30.3 | AF        | 62       | +               | -              | -   | HTN         | 17.2        | 2           |
| 14 | 69          | M   | 24.9 | PVC       |          | 48              | +              | -   | -           | 62.5        | 1           |
| 15 | 69          | M   | 20.4 | AFL       | OMI      | 66              | +              | -   | HTN, DM     | 5.1         | 0           |
| 16 | 60          | M   | 23.3 | ORT       |          | 61              | -              | -   | -           | 40          | 0           |
| 17 | 71          | M   | 29.7 | AF        | 71       | +               | -              | -   | +           | 25.1        | 1           |
| 18 | 61          | M   | 24.2 | AF        | 60       | +               | -              | -   | HTN         | 83.7        | 2           |

AF = atrial fibrillation; AFL = atrial flutter; BMI = body mass index; BNP = brain natriuretic peptide; DM = diabetes mellitus; DOAC = direct oral anticoagulant; Dx = diagnosis; HTN = hypertension; Hx = history; LVEF = left ventricular ejection fraction; NICM = nonischemic cardiomyopathy; OMI = old myocardial infarction; ORT = orthodromic reciprocating tachycardia; Pt = patient; PVC = premature ventricular contraction; PVI = pulmonary vein isolation; SAS = sleep apnea syndrome; VT = ventricular tachycardia; WF = warfarin.

*Risk scores include deep sedation, reduced left ventricular function, warfarin, atrial fibrillation, and female sex.
ablation, and PE was detected by ICE. One patient had more obvious PE with transthoracic echo than with ICE. Of 17 patients who had pericardiocentesis, 47% were of venous origin (Supplemental Table). In patients with CA for AF, 54% were of venous origin (Figure 3). Of the 15 patients who underwent AF ablation, 3 had cavotricuspid isthmus (CTI) ablation and/or superior vena cava (SVC) isolation (patients 6, 7, and 18). One patient developed PE during pulmonary vein isolation (patient 18), but pericardiocentesis stabilized the patient’s condition; therefore, CTI ablation was completed. In 2 patients, following CTI and SVC ablation, cardioversion was performed. After the cardioversion, they became hypotensive, and PE was detected. We compared the time from echo detection of the PE to pericardiocentesis. The interval was similar (median, 7.5 minutes in venous origin [IQR 5.25–22] vs 6 minutes in arterial origin [IQR 2–13.5], P = .40).

Procedure outcome

Five patients with PE resulted in failure as ablation outcome. One patient died from aortic dissection during the procedure despite emergency open heart surgery. Another patient with VT associated with nonischemic cardiomyopathy underwent CA of VT in the left ventricular endocardium after blood pressure was controlled by pericardiocentesis; however, inducibility of VT remained. In 2 patients with AF, PE was recognized after left pulmonary vein isolation, and further ablation was deferred to prevent recurrent hemorrhage with continuous anticoagulation. Of 3 AF patients, 2 underwent a second session later, which was successful.

Discussion

This study showed 2 important clinical findings: (1) gas analysis of PE during CA revealed that almost half of the drained blood was of venous origin even in AF ablation, and (2) in half of the cases, PE detection was not timed with catheter manipulation: 11% was after cardioversion, 11% was during the program stimulation for induction, and 28% was identified at the procedure end during hemostasis.

One study compared the blood gas analysis between the central vein and the PE upon pericardiocentesis. Gas analysis of PE, some of which were subacute in nature, such as following open heart surgery, showed higher pCO2, similar hematocrit, and lower pO2 than the venous blood. In our series, PE was acute in nature, but pO2 higher than the venous blood supports the arterial origin of the hemorrhage. The visualized site of perforation correlated with the gas analysis of PE in 2 patients, which might support that gas analysis helps in identifying the perforation site. Despite the usual assumption of the dominant perforation site being the left atrium for AF ablation, our study showed that over half of the cases were in the right heart, suggesting that the diagnostic catheters in the right atrium or ventricle might be responsible for the perforation. The timing of PE identification can be done anytime during the procedure, and not predominantly during RF delivery, which also supports diagnostic catheter involvement. As regards AF patients who underwent not only pulmonary vein isolation but CTI ablation and/or SVC isolation, the perforation by ablation catheter during CTI and/or SVC RF application cannot be denied. However, 5 of 12 patients who had not undergone CTI ablation and/or SVC isolation showed venous-origin blood gas, so it may be important to pay attention to catheters other than the one being manipulated. It is difficult to identify the perforation site in 1 place, except for patients with surgical repairs, because all patients who showed venous blood gas of PE used multiple diagnostic catheters for the right heart in this study. To avoid cardiac perforation, we should minimize the use of catheters as far as possible. Our usual protocol for AF ablation included adenosine triphosphate bolus to check for the dormant conduction of the pulmonary vein. Therefore, we usually use the RV catheter. We can consider the use of the RV catheter if the ventricle cannot be captured by the CS catheter. Deep sedation, reduced left ventricular function, warfarin, AF, and female sex have been reported as risk factors for PE. Of these 5 risks, they distributed from 0 to 3 points in this study. Another paper reported that no significant factors are associated with the occurrence of tamponade, including age, body mass index, sex, AF type, left atrial dimension, use of an RF needle, operators, peak ACT, and direct oral anticoagulant use except for the use of a cryoballoon. If cardiac perforation occurs, early detection of PE can prevent life-threatening cardiac tamponade. Continuous blood pressure monitoring and periodic check of cardiac motion in LAO view are useful. Given the advances in 3-dimensional electroanatomic mapping...
| Pt | His | RV | CS | Halo | Diagnostic catheter | Multipolar mapping catheter | ABL Catheter | Heparin | ACT (s) peak/last | Reasons of PE identification | Pericardio centesis | Drained blood (mL) | Gas analysis of PE | Surgery | ABL outcome | Outcome |
|----|-----|----|----|------|---------------------|-----------------------------|--------------|---------|------------------|--------------------------------|------------------|-----------------|-----------------|----------|-------------|---------|
| 1  | -   | +  | +  | -    | +                   | CF+                          | +            | 260/N.A. | Declined BP      | +                              | 800              | Artery          | Vein            | Failure  | Survived    |
| 2  | -   | +  | +  | -    | +                   | CF+                          | +            | 333/333 | LAO motion       | +                              | 190              | Vein            | Vein            | Success  | Survived    |
| 3  | -   | +  | +  | -    | +                   | CF-                          | +            | 303/N.A. | Declined BP      | +                              | 200              | Vein            | Vein            | Success  | Survived    |
| 4  | -   | +  | +  | -    | +                   | CF-                          | +            | 291/291 | Declined BP      | +                              | 125              | Vein            | -              | Success  | Survived    |
| 5  | -   | +  | +  | -    | +                   | CF-                          | +            | 254/244 | Declined BP      | +                              | 131              | Vein            | -              | Success  | Survived    |
| 6  | -   | +  | +  | -    | +                   | CF-                          | +            | 306/294 | Declined BP      | +                              | 650              | Vein            | -              | Success  | Survived    |
| 7  | -   | +  | +  | -    | +                   | CF+                          | +            | 279/N.A. | Declined BP      | +                              | 100              | Vein            | -              | Success  | Survived    |
| 8  | -   | +  | +  | -    | +                   | CF+                          | +            | 263/224 | Declined BP      | +                              | 400              | Artery          | -              | Failure  | Survived    |
| 9  | -   | +  | +  | -    | +                   | Balloon                      | +            | 304/252 | Declined BP      | +                              | 250              | Artery          | -              | Success  | Survived    |
| 10 | -   | +  | +  | -    | +                   | CF-                          | +            | 287/287 | Declined BP      | +                              | 500              | Artery          | -              | Failure  | Survived    |
| 11 | -   | +  | +  | -    | +                   | CF-                          | -            | -        | Not tested       | Declined BP                  | -                | -               | -              | Success  | Survived    |
| 12 | -   | +  | +  | -    | +                   | CF+                          | +            | 313/298 | LAO motion       | +                              | 400              | Vein            | -              | Success  | Survived    |
| 13 | -   | +  | +  | -    | +                   | CF+                          | +            | 347/N.A. | Declined BP      | +                              | 300              | Artery          | -              | Failure  | Dead        |
| 14 | -   | +  | +  | -    | +                   | CF+                          | +            | 311/271 | Declined BP      | +                              | N.A.             | Artery          | +              | Failure  | Survived    |
| 15 | -   | +  | +  | -    | +                   | CF-                          | +            | 339/230 | Declined BP      | +                              | 1000             | Vein            | +              | Success  | Survived    |
| 16 | +   | +  | +  | -    | +                   | CF+                          | +            | 249/249 | Declined BP      | +                              | 300              | Artery          | -              | Success  | Survived    |
| 17 | -   | +  | +  | -    | +                   | CF+                          | +            | 330/330 | LAO motion       | +                              | 300              | Artery          | -              | Success  | Survived    |
| 18 | -   | +  | +  | -    | +                   | CF+                          | +            | 315/246 | Declined BP      | +                              | 300              | Artery          | -              | Success  | Survived    |

ABL = ablation; ACT = activated clotting time; BP = blood pressure; CF = contact force; CS = coronary sinus; LAO = left anterior oblique; N.A. = not available; PE = pericardial effusion; Pt = patient; RV = right ventricle.
system and the ALARA (“as low as reasonably achievable”) principle, fluoroscopy use is minimized, and PE is more likely detected by blood pressure decline rather than decreased cardiac motion. In addition, ICE is useful for early detection of PE.

In this study, 1 patient died from massive PE caused by the aortic dissection. He underwent CA of the PVC, and mapping was performed retrogradely in the left ventricle and the aortic cusp. Following the successful RF ablation, reduced cardiac motion in LAO view was noticed and echocardiography showed massive PE. Immediate pericardiocentesis was unable to control the bleeding, and emergency open heart surgery was performed. However, the patient died. Autopsy showed aortic dissection from the ascending aorta to the bifurcation of the common iliac artery with severe atherosclerosis at the arch. The dissection could have been spontaneous or caused by mechanical stress. Despite detailed analysis of the autopsy, the cause remained unclear.

**Study limitations**

If arterial and venous blood are mixed through the transseptal route, it may not be accurate to identify the perforation site using only gas analysis data. However, this phenomenon is unlikely without frequent sheath or catheter removal from the left atrium. The pO₂ value in inferior pulmonary veins has been reported lower than superior pulmonary veins, and it is possible that the pO₂ value might be lower if the perforation occurs close to the ostium of inferior pulmonary veins. Second, it is unclear whether normal blood gas analysis can be applied to the accumulated PE. The reliability of the gas analysis of PE is not definite, as there were only 2 cases with visually confirmed site of perforation. Third, based on the small number of patients with PE, it is difficult to extract real trends of perforation site during various ablations.

**Clinical implication**

Care should be paid to the catheter position during cardioversion, mapping, or manipulation, since even the left heart ablation might cause perforation from the right heart.

**Conclusion**

PE caused by a diagnostic catheter seems to be common, even in AF ablation.

**Acknowledgments**

The authors thank Editage (www.editage.com) for English language editing.

**Appendix**

**Supplementary data**

Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hroo.2020.06.005.

**Funding Sources**

The authors have no funding sources to disclose.

**Disclosures**

Akiko Ueda is affiliated with the endowed department of Abbott Japan. Ikuko Togashi is affiliated with the endowed department of Medtronic. Toshiaki Sato is affiliated with the endowed department of Biotronik. The other authors report no conflicts of interest.

**References**

1. Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009;53:1798–1803.
2. Murakawa Y, Yamane T, Goya M, et al. Incidence and predictors of pericardial effusion as an early complication of catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAP). J Arrhythm 2017;33:430–433.
3. Lane JD, Cannie D, Volkova E, et al. Anticoagulation and the risk of complications in ventricular tachycardia and premature ventricular complex ablation. Pacing Clin Electrophysiol 2018;41:1454–1460.
4. Cheung JW, Yeo I, Ip JE, et al. Outcomes, costs, and 30-day readmissions after catheter ablation of myocardial infarct-associated ventricular tachycardia in the real world: nationwide readmissions database 2010 to 2015. Circ Arrhythm Electrophysiol 2018;11:e006754.

![Figure 2](image-url) Timing of pericardial effusion detection. The timing of the pericardial effusion detection is depicted with tags. Blue tag represents atrial fibrillation, green tag represents premature ventricular contraction, yellow tag represents ventricular tachycardia, gray tag represents atrial flutter, and pink tag represents orthodromic reciprocating tachycardia. CA = catheter ablation.

![Figure 3](image-url) Gas analysis of pericardial effusion. A: Percentage of gas analysis of the pericardial effusion of all patients with pericardiocentesis. B: Percentage of gas analysis of the pericardial effusion in atrial fibrillation (AF).
5. Yu HP, Feng AN, Tsai SK, Hsiung MC, Yin WH. Transcatheter repair of iatrogenic aortic perforation complicating transseptal puncture for a catheter ablation of atrial arrhythmia. Acta Cardiol Sin 2014;30:490–492.

6. Brunelli M, Frommhold M, Back D, Mierzwia M, Lauer B, Geller JC. Isolated disruption of the right coronary artery following a steam pop during cavotricuspid linear ablation with a contact force catheter. Pacing Clin Electrophysiol 2016;39:771–773.

7. Bunch TJ, Asirvatham SJ, Friedman PA, et al. Outcomes after cardiac perforation during radiofrequency ablation of the atrium. J Cardiovasc Electrophysiol 2005;16:1172–1179.

8. Byrne AL, Bennett M, Chatterji R, Symons R, Pace NL, Thomas PS. Peripheral venous and arterial blood gas analysis in adults: are they comparable? A systematic review and meta-analysis. Respirology 2014;19:168–175.

9. Balakrishnan S, Hartman CW, Grinnan GL, Bartel AG, Crisler C, Brickman RD. Pericardial fluid gas analysis in hemorrhagic pericardial tamponade. Ann Thorac Surg 1979;27:55–58.

10. Lan L, Zeng Y, Wang WR, et al. Clinical characteristics and risk factors of pericardial effusion complicating radiofrequency catheter ablation in Chinese Han patients with tachyarrhythmias. Herz 2013;38:909–914.

11. Hamaya R, Miyazaki S, Taniguchi H, et al. Management of cardiac tamponade in catheter ablation of atrial fibrillation: single-centre 15 year experience on 5222 procedures. Europace 2018;20:1776–1782.

12. Yamane T, Date T, Tokuda M, et al. Hypoxemia in inferior pulmonary veins in supine position is dependent on obesity. Am J Respir Crit Care Med 2008;178:295–299.